Zobrazeno 1 - 10 of 172 pro vyhledávání: '"Jyothis T, George"'
1
Akademický článek
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
Autor: David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad
Publikováno v: ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
Abstract Aims In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV)
Externí odkaz: https://doaj.org/article/6f3f85051982443390d12385e07f958a
Zobrazit plný text záznamu
2
Akademický článek
Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Autor: Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Publikováno v: ESC Heart Failure, Vol 8, Iss 4, Pp 2580-2590 (2021)
Abstract Aims Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium‐glucose co‐transporter‐2 inhibitor empagliflozin demonstrated significant reductions of HF hospi
Externí odkaz: https://doaj.org/article/70e5e797e27347219ca852428a66c514
Zobrazit plný text záznamu
3
Akademický článek
Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
Autor: Odette S. Reifsnider, Anuraag R. Kansal, Jennifer Franke, Joseph Lee, Jyothis T. George, Martina Brueckmann, Stefan Kaspers, Sarah B. Brand, Anastasia Ustyugova, Stephan Linden, Matthew Stargardter, Nikco Hau
Publikováno v: ESC Heart Failure, Vol 7, Iss 6, Pp 3910-3918 (2020)
Abstract Aims Heart failure (HF) and type 2 diabetes (T2D), common co‐morbidities, translate into worse patient prognoses and higher direct costs than for either condition alone. Empagliflozin has been shown to markedly reduce cardiovascular (CV) d
Externí odkaz: https://doaj.org/article/b6cdbfab1d4b4a70926b8d6191514435
Zobrazit plný text záznamu
4
Akademický článek
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
Autor: Darren K. McGuire, Silvio E. Inzucchi, Odd Erik Johansen, Julio Rosenstock, Jyothis T. George, Nikolaus Marx
Publikováno v: Journal of Pharmaceutical Policy and Practice, Vol 14, Iss 1 (2021)
Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either
Externí odkaz: https://doaj.org/article/d10cb6666c9b4412859efa118e071efc
Zobrazit plný text záznamu
5
Akademický článek
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Autor: João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, Sabine Lauer, Bernard Zinman, David H. Fitchett, Audrey Koitka‐Weber, Jyothis T. George, Anne Pernille Ofstad, Christoph Wanner, Faiez Zannad
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 7 (2021)
Background Cardio/kidney composite end points are clinically relevant but rarely analyzed in cardiovascular trials. This post hoc analysis of the EMPA‐REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patient
Externí odkaz: https://doaj.org/article/84d680b85e504deea50cb92bed7c4a4b
Zobrazit plný text záznamu
7
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
Autor: Anne Pernille Ofstad, Afshin Salsali, Erich Bluhmki, Martin Schumacher, Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Stefan Hantel, Kristin Ohneberg, Jyothis T. George, Claudia Schmoor, David Fitchett, Faiez Zannad, Bernard Zinman
Publikováno v: ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
International audience; Aims: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c9cd3965f69a6842aa5748f13ebd7d
https://doi.org/10.1002/ehf2.13615
Zobrazit plný text záznamu
8
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes
Autor: Christoph Wanner, Isabella Zwiener, Robert J. Mentz, Jyothis T. George, Abhinav Sharma, David Fitchett, Nihar R. Desai, Bernard Zinman, Anne Pernille Ofstad, Stefan Hantel, Tariq Ahmad
Publikováno v: JACC: Heart Failure. 9:568-577
Objectives Using latent class analysis (LCA) of EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), this study identified d...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8309ebe470180d8fe8154900de90b795
https://doi.org/10.1016/j.jchf.2021.03.003
Zobrazit plný text záznamu
9
Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Autor: Eleanor Wicks, Hanan Lamlum, Jyothis T. George, Olorunsola F. Agbaje, Christopher T. Rodgers, Rury R. Holman, Oliver J Rider, Ladislav Valkovič, Heiko G. Niessen, Rolf Grempler, Stefan Neubauer, Moritz Hundertmark, Joanne E. Milton, Jisoo Lee, Ruth L. Coleman, Masliza Mahmod
Publikováno v: ESC Heart Failure, Vol 8, Iss 4, Pp 2580-2590 (2021)
ESC Heart Failure
Aims Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium-glucose co-transporter-2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c963ade06b856a2fa857cae15b1d938c
https://doaj.org/article/70e5e797e27347219ca852428a66c514
Zobrazit plný text záznamu
10
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
Autor: Odd Erik Johansen, Christoph Wanner, Isabella Zwiener, Subodh Verma, Javed Butler, Jyothis T. George, Bernard Zinman, Silvio E. Inzucchi, C. David Mazer, Anne Pernille Ofstad
Publikováno v: Diabetes, Obesity & Metabolism
Aim To determine the relationship between polyvascular disease and risk of hospitalization for heart failure (HHF) and cardiovascular (CV) death in the EMPA‐REG OUTCOME population, and the relationship of kidney dysfunction co‐existent with polyv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0613037c00a7cfe489e36a64edb67ced
https://doi.org/10.1111/dom.14326
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje